SCHEMBL2090766

SCHEMBL2090766

Cc1ccccc1COCC1CC[N]CC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 0.42
ADRA2B P18089 1/20 0.42
ADRA2C P18825 1/20 0.42
CHRNB2 P17787 1/20 0.37
CHRNA4 P43681 1/20 0.37
ACHE P22303 1/20 0.36
GRIN2B Q13224 1/20 0.36
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
TACR1 P25103 2/20 0.35
ALDH1A1 P00352 1/20 0.35
GLA P06280 1/20 0.35
RIPK1 Q13546 1/20 0.35
FFAR1 O14842 2/20 0.34
CYP2A13 Q16696 1/20 0.34
MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2094717 0.88 ESR1 (0.34) ADRA2AADRA2BADRA2CCHRNB2CHRNA4
SCHEMBL2088996 0.82 IDO1 (0.46) DRD2DRD4TACR1ALDH1A1RIPK1
SCHEMBL2094881 0.78 MEN1 (0.41) ADRA2AADRA2BADRA2CACHE
SCHEMBL3122115 0.78 EPHX2 (0.45) ADRA2AADRA2BADRA2CACHEDRD4
SCHEMBL2096177 0.77 CTSL (0.50) CHRNB2CHRNA4
SCHEMBL20739380 0.75 ALDH1A1 (0.38) ADRA2AADRA2BADRA2CCHRNB2CHRNA4
SCHEMBL28407405 0.75 ALDH1A1 (0.56) ADRA2AADRA2BADRA2CACHEALDH1A1
SCHEMBL4315585 0.73 TAAR1 (0.50) ADRA2AADRA2BADRA2CACHEALDH1A1
SCHEMBL11354598 0.72 HRH4 (0.40) ADRA2AADRA2BADRA2CACHETACR1
SCHEMBL11353120 0.72 HRH4 (0.38) ADRA2AADRA2BADRA2CACHETACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 ADRA2A 583/4885ADRA2B 317/4885ADRA2C 468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.